"At all 3 presentations (Sept, Nov, Jan), they state that the occurence rate is 10-15 per month.  That means it has been 10-15 in the months prior to the September statement, all the way through to Jan 7th.  How is that not the ACTUAL event rate?  How could it be less than 10?"

Resverlogix never disclosed what time period range they were using to calculate the 10-15 events per month range. It cannot be the event rate for the entire trial period starting from Nov 2015 to current or 250 events would have been surpassed long ago. So uncertainty #1 is the time range.

At the AGM on 9/12/2018 and Bio-Europe in Nov 2018, the 10-15 events per month statement was also accompanied by the statement that end of dosing was expected by the end of 2018. Resverlogix dropped the end of dosing by end of 2018 statement from their December 2018 Corporate Presentation as well as the recent January 2019 presentation. So uncertainty #2 is a) Are we still on track for the low end of the range of 10 per month, which demands 250 by Feb 12th? b) Did the goal post get moved due to the rate being below 10 per month, pushing the 250 event mark to beyond Feb 12th? or c) Have 250 non-adjudicated events already been reached but no official announcement made?

25 days to go for Feb 12th, then Resverlogix needs to explain their math!

BDAZ